Education
About Us
Working with TipRanks
Follow Us
PILA PHARMA AB (SE:PILA)
:PILA
PILA Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr2.50 - kr9.20
Previous CloseN/A
Volume9.62K
Average Volume (3M)23.02K
Market Cap
kr85.45M
Enterprise ValueN/A
Total Cash (Recent Filing)kr2.54M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding27,126,623
10 Day Avg. Volume30,666
30 Day Avg. Volume23,022
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)15.33
Price to Sales (P/S)0.00
P/FCF Ratio-18.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PILA FAQ
What was PILA PHARMA AB’s price range in the past 12 months?
PILA PHARMA AB lowest stock price was kr2.50 and its highest was kr9.20 in the past 12 months.
What is PILA PHARMA AB’s market cap?
PILA PHARMA AB’s market cap is kr85.45M.
When is PILA PHARMA AB’s upcoming earnings report date?
PILA PHARMA AB’s upcoming earnings report date is Aug 27, 2025 which is in 90 days.
How were PILA PHARMA AB’s earnings last quarter?
Currently, no data Available
Is PILA PHARMA AB overvalued?
According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued.
Does PILA PHARMA AB pay dividends?
PILA PHARMA AB does not currently pay dividends.
What is PILA PHARMA AB’s EPS estimate?
PILA PHARMA AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PILA PHARMA AB have?
PILA PHARMA AB has 27,126,623 shares outstanding.
What happened to PILA PHARMA AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PILA PHARMA AB?
Currently, no hedge funds are holding shares in SE:PILA
Company Description
PILA PHARMA AB
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Technical Analysis
Biosergen AB
―
OncoZenge AB
―
Biovica International AB Class B
―
Active Biotech AB
―
Spago Nanomedical AB
―